Samlyn Capital LLC Has $141.08 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Samlyn Capital LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 54.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,760,276 shares of the company’s stock after purchasing an additional 2,745,015 shares during the period. Kenvue comprises 2.4% of Samlyn Capital LLC’s holdings, making the stock its 12th largest holding. Samlyn Capital LLC’s holdings in Kenvue were worth $141,082,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Davidson Kempner Capital Management LP boosted its position in shares of Kenvue by 15.0% during the 2nd quarter. Davidson Kempner Capital Management LP now owns 4,029,352 shares of the company’s stock worth $73,254,000 after acquiring an additional 525,614 shares in the last quarter. Bank of Montreal Can boosted its position in Kenvue by 103.5% in the second quarter. Bank of Montreal Can now owns 3,707,447 shares of the company’s stock valued at $67,401,000 after buying an additional 1,885,869 shares in the last quarter. Magnetar Financial LLC bought a new position in shares of Kenvue during the second quarter valued at $12,303,000. Public Sector Pension Investment Board raised its stake in shares of Kenvue by 92.9% during the second quarter. Public Sector Pension Investment Board now owns 73,637 shares of the company’s stock valued at $1,339,000 after acquiring an additional 35,461 shares during the last quarter. Finally, DRW Securities LLC bought a new position in shares of Kenvue during the second quarter valued at $205,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $23.02 on Tuesday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $23.55. The stock has a market capitalization of $44.08 billion, a P/E ratio of 29.51, a P/E/G ratio of 2.92 and a beta of 1.40. The company has a 50-day moving average price of $21.02 and a 200-day moving average price of $19.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The business had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. During the same period in the previous year, the company earned $0.32 earnings per share. The firm’s revenue for the quarter was down .3% compared to the same quarter last year. On average, equities research analysts forecast that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were given a $0.205 dividend. The ex-dividend date was Wednesday, August 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.56%. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s payout ratio is 105.13%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. UBS Group lifted their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Piper Sandler lifted their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Monday. Citigroup decreased their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $21.56.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.